Status:
RECRUITING
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Conditions:
B-cell Non-Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to assess the efficacy and safety in the real-world settings of glofitamab in combination with salvage therapy among Chinese adult patients with relapsed or refractory B-c...
Eligibility Criteria
Inclusion
- Be diagnosed as B-NHL
- Relapse or refractory to previous treatment
- Participants who will be treated with glofitamab
Exclusion
- Participant who currently participates in or with plan to participate in any interventional clinical trial
- Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
Key Trial Info
Start Date :
June 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06497452
Start Date
June 1 2024
End Date
June 1 2026
Last Update
July 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215000